Zydus shares move up after getting tentative USFDA approval for Dapagliflozin 5 mg and 10 mg tablets
News by Aliceblue News Desk
04 Feb 2026
Introduction
Leading pharmaceutical company received tentative USFDA approval for Dapagliflozin 5 mg and 10 mg tablets to improve glycaemic control in adults with type 2 diabetes.
Also Read: Kranti Industries moves up 10% after securing Defence PSU order for machining precision components
Share price movement of Zydus Lifesciences
On February 4, 2026, Zydus Lifesciences Ltd opened at ₹907.00, up 0.11% from its previous close of ₹902.95. The stock reached a high of ₹912.15 (1.02%) and a low of ₹899.35. By 3:09 PM, it traded at ₹905.20, a 0.25% increase, with a market cap of ₹91,084.30 crore.
Zydus Gets USFDA Approval for Dapagliflozin
Zydus Lifesciences Limited received tentative approval from the USFDA for Dapagliflozin Tablets, 5 mg and 10 mg, used to improve glycaemic control in adults with type 2 diabetes.
The tablets, equivalent to Farxiga®, will be manufactured at Zydus’ formulation facility in SEZ, Ahmedabad. The US market for Dapagliflozin had annual sales of USD 10,486.9 million as of December 2025.
As on 31-Dec-2025, Zydus has filed 505 ANDAs and received 430 approvals. This approval adds to the company’s growing portfolio of generic formulations for international markets.
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd delivered a 0.67% return over the past week, declined 3.55% in the past 6 months, and fell 7.30% over the past 1 year.
Also Read: KEC International gains 6% after bagging new orders worth ₹1,020 Cr
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75% | 75.00% | 75.00% |
| FII | 7% | 7% | 7% |
| DII | 11% | 11% | 11.10% |
| Public | 6.90% | 6.80% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE), formerly Cadila Healthcare, focuses on healthcare innovation, addressing unmet medical needs, and creating healthier communities globally with significant financial growth.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price rising today?
A: Zydus Lifesciences receives tentative USFDA approval for Dapagliflozin 5 mg and 10 mg tablets for type 2 diabetes treatment.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences Ltd focuses on healthcare innovation, pharmaceutical manufacturing, and addressing unmet medical needs globally.
Q: What are the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd recorded a 52-week high of ₹1,059.00 and a low of ₹797.05.
News Author
Aliceblue News Desk
